Haifa Kathrin Al-Ali, MD of the University of Leipzig, Leipzig, Germany, gives an overview of the results of the multicenter, expanded access JUMP trial of ruxolitinib for myelofibrosis patients (NCT01493414). She highlights the importance of evaluating safety, given toxicity issues had with other JAK inhibitors. The trial has given more data on safety for this treatment, for a wide range of patients, in different countries. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

свернуть